Profilaxis postexposición al VIH (PPE) | 26 DIC 18
Cómo actuar ante un caso de exposición al virus VIH
La profilaxis postexposición posible o real (PPE) al VIH es segura y eficaz para prevenir la infección. Es una modalidad preventiva para personas con exposición reciente (dentro de las 72 horas) al virus
1
19
Autor: Siedner M, Tumarkin E, Bogoch I Fuente: BMJ 2018;363  HIV post-exposure prophylaxis (PEP)
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Tan DHS, Hull MW, Yoong D, etal. Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017; 189:E1448-58. 10.1503/cmaj.170494 29180384

2 Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV–United States, 2016. Morbidity and Mortality Weekly Report. https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf.

3 Rodger AJ, Cambiano V, Bruun T, etal. PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016; 316:171-81. 10.1001/jama.2016.5148 27404185

4 Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS 2014; 28:1509-19. 10.1097/QAD.0000000000000298 24809629

5 Cresswell F, Waters L, Briggs E, etal . UK guideline for the use of HIV post-exposure prophylaxis following sexual exposure, 2015. Int J STD AIDS 2016; 27:713-38. 10.1177/0956462416641813 27095790

6 World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: Recommendations for a public health approach: December 2014—supplement to the 2013 consolidated ARV guidelines. 2014. https://www.who.int/hiv/pub/guidelines/ arv2013/arvs2013upplement_dec2014/en/ 7 Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018; 379:979-81. 10.1056/NEJMc1807653 30037297

8 Tokars JI, Marcus R, Culver DH, etal. The CDC Cooperative Needlestick Surveillance Group. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993; 118:913-9. 10.7326/0003-4819-118-12-199306150-00001 8387737

9 Roland ME, Neilands TB, Krone MR, etal . Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005;41: 1507-13. 10.1086/497268 16231265

10 Sonder GJB, Prins JM, Regez RM, etal . Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis 2010; 37:681-6. 10.1097/OLQ.0b013e3181e2f999 20644499

11 Jain S, Oldenburg CE, Mimiaga MJ, Mayer KH. Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013. AIDS Patient Care STDS 2015; 29:20-5. 10.1089/apc.2014.0154 25369451

12 Tsai CC, Emau P, Follis KE, etal . Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72: 4265-73.9557716

13 Otten RA, Smith DK, Adams DR, etal . Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74:9771-5. 10.1128/JVI.74.20.9771-9775.2000 11000253

14 Australian National Guidelines. Post-exposure prophylaxis after non-occupational and occupational exposure to HIV. http://www.pep.guidelines.org.au/index.php/prescribingpep/ medications-and-cautions.

15 Bogoch II, Scully EP, Zachary KC, etal . Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis. Clin Infect Dis 2014; 58:1618-24. 10.1093/cid/ciu118 24723288

16 Siemieniuk RAC, Sivachandran N, Murphy P, etal . Transitioning to HIV pre-exposure prophylaxis (PrEP) from non-occupational post-exposure prophylaxis (nPEP) in a comprehensive HIV prevention clinic: a prospective cohort study. AIDS Patient Care STDS 2015;29:431-6. 10.1089/apc.2015.0014 26154174

17 Tumarkin E, Siedner M, Bogoch II. HIV pre-exposure prophylaxis (PrEP). BMJ [forthcoming].

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí